Access without Excess: Bedaquiline
Global Health Policy Forum: “Access to New Medicines”

Myriam Theeuwes, Compound Development Team Leader
December 12, 2016

Access: When Most Needed

>800 patients in 47 countries

Early Access Programs:
- Russia & Lithuania
  - N=57
- ATU France
  - N=194
- Compassionate Use Global
  - N=554
> 80% of the world's MDR-TB burden has regulatory access to bedaquiline at the end of 2016.
**Access: Global Drug Facility**

A UN Operations organization within the STOP TB Department, the GDF is the largest global supplier of quality-assured anti-TB treatments.

- Adult, pediatric drug sensitive and drug resistant regimens
- WHO prequalified drugs and innovative drugs
- User-friendly diagnostic kits
- Sales to more than 133 countries
- Technical assistance to improve drug management systems
- Pioneered a standard 4-language package global package

Administration and oversight of a regulatory waiver process has contributed to significant advances in patient access to treatments.

---

**Janssen Contributions: Beyond the Pill**

**Breath for Life**
A pilot to increase childhood TB case detection, treatment, and prevention in Viet Nam.
Janssen & South Africa: A New Paradigm in Collaboration

- Infection control
- Portable audiometers
- Patient support

- Data management
- MDR-TB registry
- Advisory Boards

- HCW Training
- Antibacterial surveillance
- Disease awareness
- Website (whatistb.com)

A story of successful private public partnership
Introduction of bedaquiline into the National TB programme of South Africa

There is an urgent need to improve the outcomes of MDRTB patients. "In the traditional TB treatment, there is a lot of留给 and resistant drug-novel solutions that have not been adopted in the country."

"These include bedaquiline and delamanid. Resistance control directed at these drugs is an opportunity to improve these drugs into effective regimens.

"There is a need for urgent access to these drugs to patients with the treatment options remaining. Antiretroviral therapy to be taken to combat HIV and to prevent the development of drug resistance.

With all these factors, the administration of a single dose of bedaquiline is recommended for patients with drug-resistant tuberculosis.
Questions?

Thank you!